277 related articles for article (PubMed ID: 19843847)
1. ATAD2 is a novel cofactor for MYC, overexpressed and amplified in aggressive tumors.
Ciró M; Prosperini E; Quarto M; Grazini U; Walfridsson J; McBlane F; Nucifero P; Pacchiana G; Capra M; Christensen J; Helin K
Cancer Res; 2009 Nov; 69(21):8491-8. PubMed ID: 19843847
[TBL] [Abstract][Full Text] [Related]
2. Disruption of the pRb/E2F pathway and inhibition of apoptosis are major oncogenic events in liver constitutively expressing c-myc and transforming growth factor alpha.
Santoni-Rugiu E; Jensen MR; Thorgeirsson SS
Cancer Res; 1998 Jan; 58(1):123-34. PubMed ID: 9426068
[TBL] [Abstract][Full Text] [Related]
3. Adenovirus E1A oncoprotein liberates c-Myc activity to promote cell proliferation through abating Bin1 expression via an Rb/E2F1-dependent mechanism.
Kinney EL; Tanida S; Rodrigue AA; Johnson JK; Tompkins VS; Sakamuro D
J Cell Physiol; 2008 Sep; 216(3):621-31. PubMed ID: 18348166
[TBL] [Abstract][Full Text] [Related]
4. E2F activity is essential for survival of Myc-overexpressing human cancer cells.
Santoni-Rugiu E; Duro D; Farkas T; Mathiasen IS; Jäättelä M; Bartek J; Lukas J
Oncogene; 2002 Sep; 21(42):6498-509. PubMed ID: 12226753
[TBL] [Abstract][Full Text] [Related]
5. Cyclin E and c-Myc promote cell proliferation in the presence of p16INK4a and of hypophosphorylated retinoblastoma family proteins.
Alevizopoulos K; Vlach J; Hennecke S; Amati B
EMBO J; 1997 Sep; 16(17):5322-33. PubMed ID: 9311992
[TBL] [Abstract][Full Text] [Related]
6. A novel factor distinct from E2F mediates C-MYC promoter activation through its E2F element during exit from quiescence.
Alvaro-Blanco J; Martínez-Gac L; Calonge E; Rodríguez-Martínez M; Molina-Privado I; Redondo JM; Alcamí J; Flemington EK; Campanero MR
Carcinogenesis; 2009 Mar; 30(3):440-8. PubMed ID: 19126644
[TBL] [Abstract][Full Text] [Related]
7. Vitamin E succinate inhibits proliferation of BT-20 human breast cancer cells: increased binding of cyclin A negatively regulates E2F transactivation activity.
Turley JM; Ruscetti FW; Kim SJ; Fu T; Gou FV; Birchenall-Roberts MC
Cancer Res; 1997 Jul; 57(13):2668-75. PubMed ID: 9205075
[TBL] [Abstract][Full Text] [Related]
8. p120-v-Abl expression overcomes TGF-beta1 negative regulation of c-myc transcription but not cell growth.
Birchenall-Roberts MC; Kim SJ; Bertolette DC; Turley JM; Fu T; Bang OS; Kasper JJ; Yoo YD; Ruscetti FW
Oncogene; 1996 Oct; 13(7):1499-509. PubMed ID: 8875988
[TBL] [Abstract][Full Text] [Related]
9. A direct role of transcription factor E2F in c-myc gene expression during granulocytic and macrophage-like differentiation of HL60 cells.
Ishida S; Shudo K; Takada S; Koike K
Cell Growth Differ; 1995 Mar; 6(3):229-37. PubMed ID: 7794791
[TBL] [Abstract][Full Text] [Related]
10. E2F-HDAC complexes negatively regulate the tumor suppressor gene ARHI in breast cancer.
Lu Z; Luo RZ; Peng H; Huang M; Nishmoto A; Hunt KK; Helin K; Liao WS; Yu Y
Oncogene; 2006 Jan; 25(2):230-9. PubMed ID: 16158053
[TBL] [Abstract][Full Text] [Related]
11. Dual control of myc expression through a single DNA binding site targeted by ets family proteins and E2F-1.
Roussel MF; Davis JN; Cleveland JL; Ghysdael J; Hiebert SW
Oncogene; 1994 Feb; 9(2):405-15. PubMed ID: 8290253
[TBL] [Abstract][Full Text] [Related]
12. BRD7, a novel bromodomain gene, inhibits G1-S progression by transcriptionally regulating some important molecules involved in ras/MEK/ERK and Rb/E2F pathways.
Zhou J; Ma J; Zhang BC; Li XL; Shen SR; Zhu SG; Xiong W; Liu HY; Huang H; Zhou M; Li GY
J Cell Physiol; 2004 Jul; 200(1):89-98. PubMed ID: 15137061
[TBL] [Abstract][Full Text] [Related]
13. Interaction and functional cooperation of the cancer-amplified transcriptional coactivator activating signal cointegrator-2 and E2F-1 in cell proliferation.
Kong HJ; Yu HJ; Hong S; Park MJ; Choi YH; An WG; Lee JW; Cheong J
Mol Cancer Res; 2003 Nov; 1(13):948-58. PubMed ID: 14638867
[TBL] [Abstract][Full Text] [Related]
14. p27kip1-independent cell cycle regulation by MYC.
Berns K; Martins C; Dannenberg JH; Berns A; te Riele H; Bernards R
Oncogene; 2000 Oct; 19(42):4822-7. PubMed ID: 11039898
[TBL] [Abstract][Full Text] [Related]
15. New Myc-interacting proteins: a second Myc network emerges.
Sakamuro D; Prendergast GC
Oncogene; 1999 May; 18(19):2942-54. PubMed ID: 10378691
[TBL] [Abstract][Full Text] [Related]
16. c-Myc-regulated microRNAs modulate E2F1 expression.
O'Donnell KA; Wentzel EA; Zeller KI; Dang CV; Mendell JT
Nature; 2005 Jun; 435(7043):839-43. PubMed ID: 15944709
[TBL] [Abstract][Full Text] [Related]
17. Down-regulation of signal transducer and activator of transcription 3 expression using vector-based small interfering RNAs suppresses growth of human prostate tumor in vivo.
Gao L; Zhang L; Hu J; Li F; Shao Y; Zhao D; Kalvakolanu DV; Kopecko DJ; Zhao X; Xu DQ
Clin Cancer Res; 2005 Sep; 11(17):6333-41. PubMed ID: 16144938
[TBL] [Abstract][Full Text] [Related]
18. Autorepression of c-myc requires both initiator and E2F-binding site elements and cooperation with the p107 gene product.
Luo Q; Li J; Cenkci B; Kretzner L
Oncogene; 2004 Feb; 23(5):1088-97. PubMed ID: 14716294
[TBL] [Abstract][Full Text] [Related]
19. c-myc-enhanced S phase entry in keratinocytes is associated with positive and negative effects on cyclin-dependent kinases.
Alexandrow MG; Moses HL
J Cell Biochem; 1998 Sep; 70(4):528-42. PubMed ID: 9712150
[TBL] [Abstract][Full Text] [Related]
20. E2F-dependent regulation of human MYC: trans-activation by cyclins D1 and A overrides tumour suppressor protein functions.
Oswald F; Lovec H; Möröy T; Lipp M
Oncogene; 1994 Jul; 9(7):2029-36. PubMed ID: 8208548
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
